Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease

Current Diabetes Reports

Volumn 4, Issue 6, 2004, Pages 441-446

  Williams, Mark E ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTINUCLEAR ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLYCOSYLATED ALBUMIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PROTEOGLYCAN; PYRIDOXAMINE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANEMIA; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; HYPERGLYCEMIA; INHIBITION KINETICS; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN CROSS LINKING; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RECEPTOR UPREGULATION; REVIEW;

EID: 12144257117     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0054-0     Document Type: Review

References (47)

1. Locatelli F, Canaud B, Eckardt KU, et al.: The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003, 8:716-1725.
2. Gordois A, Scuffham P, Shearer A, et al.: The health rare costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004, 18:18-26.
3. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes control and Complications Trial. Diabetes Control and Complications (DCCT) Research Group [no authors listed]. Kidney Int 1995, 47:1703-1720.
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
5. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329: 456-1462.
7. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321.
8. Williams ME: New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003, 41(3 suppl 1):S42-S47.
9. Caramori ML, Mauer M: Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003, 12:273-282.
10. Raj DSC, Choudhury D, Welbourne TC, Levi M: Advanced glycation end-products: a nephrologist's perspective. Am J Kidney Dis 2000, 35:365-380.
11. Mene P, Festuccia F, Pugliese F: Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus. Am J Cardiovasc Drugs 2003, 3:315-320.
12. Rahbar S, Figarola JL: Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003, 419: 3-79.
13. Singh R, Barden A, Mori T, Beilin L: Advanced glycation endproducts: a review. Diabetologia 2001, 44:129-146.
14. Costantino L, Rastelli G, Gamberini MC, et al.: Pharmacological approaches to the treatment of diabetic complications. Expert Opin Ther Patents 2000, 10:1245-1262.
15. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-819.
16. Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and progressive course of renal disease. Am J Kidney Dis 2001, 38:S100-S106.
17. Sabbatini M, Sansone G, Uccello F, et al.: Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 1992, 42:875-881.
18. McVerry BA, Hopp AF, Huehns RR: Production of pseudodiabetic renal glomerular changes in mice after repeated injections of glycosylated proteins. Lancet 1980, 2:738-740.
19. Lee HB, Cha MK, Song KI, et al.: Pathogenic role of advanced glycosylation end products in diabetic nephropathy. Kidney Int 1997, 60:S60-S65.
20. Sakurai S, Yonekura H, Yamamoto Y: The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 2003, 8:S259-S263.
21. Forbes JM, Cooper ME, Oldfield MD, et al.: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S254-S258.
22. Thornalley PJ: Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003, 419:31-40.
23. Youseff S, Nguyen DJ, Soulis T, et al.: Effects of diabetes and aminoguanidine therapy in renal advanced glycation endproduct binding. Kidney Int 1999, 55:907-916.
24. Abdel-Rahman E, Bolton WK: Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002, 11: 65-574.
25. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992, 41:26-29.
26. Bolton WK, Cattran DC, Williams ME, et al.: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004, 24: 2-40.
27. Metz TO, Alderson NL, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003, 419:41-49.
28. Voziyan PA, Metz TO, Baynes JW, Hudson BG: A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 2002, 277:3397-3403.
29. Amarnath V, Amarnath K, Amarnath K, et al.: Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. Chem Res Toxicol 2004, 17:410-415.
30. Voziyan PA, Khalifah RG, Thibaudeau C, et al.: Modification of proteins in vitro by physiological levels of glucose Pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox meta ions. J Biol Chem 2003, 47:46616-46624.
31. Onorato JM, Jenkins AJ, Thorpe SR, et al.: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J Bio Chem 2000, 275: 1177-21184.
32. Degenhardt TP, Alderson NL, Arrington DD: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002, 61:939-950.
33. Alderson NL, Chachich ME, Youssef NY, et al.: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003, 63: 123-2133.
34. Williams M: A phase 2 clinical trial of Pyridorin in type 1 diabetic patients witla overt nephropathy (PYR-206). J Am Soc Nephrol 2003, 14:7A.
35. McGill JB, Degenhardt TP, Szabo JR, et al.: A phase 2 clinical investigation of pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR-205/207) [abstract]. Diabetes 2003, 53:581.
36. Wassenberg JJ, Knight ST, Fox JW, et al.: The AGE inhibitor pyridoxamine (Pyridorin) reduces urinary TGF-B1 in diabetic patients with overt nephropathy. J Am Soc Nephrol 2003, 14: 59A.
37. Sharma R, Khanna A, Sharma M, Savin VJ: Transforming growth factor Beta-1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 2000, 58: 31-136.
38. Khalifah RG, Baynes JW, Hudson BG: Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Comm 1999, 257:251-258.
39. Wolffenbuttel BH, Boulanger CM, Crijns FR, et al.: Breakers of advanced glycation end products restore larger arterial properties in experimental diabetes. Proc Natl Acad Sci U S A 1998, 14:4630-4634.
40. Candido R, Forbes JM, Thomas MC, et al.: A breaker of advanced glycation end products attenuates diabetic induced myocardial structural changes. Circ Res 2003, 18:785-792.
41. Susic D, Varagic J, Ahn J, et al.: Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 2004, 19:336-340.
42. Kass DA, Shapiro EP, Kawaguchi M, et al.: Improved arterial compliance by a novel advanced glycation end product crosslink breaker. Circulation 2001, 25:1464-1470.
43. Vasan S, Foiles P, Founds H: Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003, 419:89-96.
44. Cohen MP, Shea E, Chen S, et al.: Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 2003, 141:242-249.
45. Chen S, Cohen MP, Lautenslager Gr, et al.: Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 2001, 59:673-681.
46. Amore A, Cirina P, Conti G, et al.: Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. Nephrol Dial Transplant 2004, 19:53-60.
47. Cohen MP, Hud E, Shea E, et al.: Normalizing glycated albumin reduces increased urinary collagen IV and prevents renal insufficiency in diabetic db/db mice. Metabolism 2002, 51: 01-905.